{"id":121813,"date":"2021-05-08T09:02:12","date_gmt":"2021-05-08T01:02:12","guid":{"rendered":"http:\/\/www.namnewsnetwork.org\/?p=121813"},"modified":"2021-05-08T09:02:16","modified_gmt":"2021-05-08T01:02:16","slug":"covid-19-who-approves-chinas-sinopharm-vaccine","status":"publish","type":"post","link":"http:\/\/namnewsnetwork.org\/?p=121813","title":{"rendered":"Covid-19: WHO approves China\u2019s Sinopharm vaccine"},"content":{"rendered":"\n<figure class=\"wp-block-image\"><a href=\"http:\/\/www.bssnews.net\/wp-content\/uploads\/2021\/05\/1-15.jpg\"><img src=\"http:\/\/www.bssnews.net\/wp-content\/uploads\/2021\/05\/1-15.jpg\" alt=\"\"\/><\/a><\/figure>\n\n\n\n<p>GENEVA, May 8 (NNN-AGENCIES) &#8212; The World Health Organization has approved the Sinopharm Covid-19 vaccine for emergency use \u2014 the first Chinese jab to receive the WHO\u2019s green light.<\/p>\n\n\n\n<p>The UN health agency signed off on the two-dose vaccine, which is already being deployed in dozens of countries around the world.<\/p>\n\n\n\n<p>The WHO has already given emergency use listing to the vaccines being made by Pfizer-BioNTech, Moderna, Johnson and Johnson, and the AstraZeneca jab being produced at separate sites in India and in South Korea.<\/p>\n\n\n\n<p>\u201cThis (Friday) afternoon, WHO gave emergency use listing to Sinopharm Beijing\u2019s Covid-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality,\u201d WHO chief Tedros Adhanom Ghebreyesus told a news conference.<\/p>\n\n\n\n<p>\u201cThe Strategic Advisory Group of Experts on Immunisation, or SAGE, has also reviewed the available data, and recommends the vaccine for adults 18 years and older, with a two-dose schedule.\u201d<\/p>\n\n\n\n<p>An emergency use listing by the WHO paves the way for countries worldwide to quickly approve and import a vaccine for distribution, especially those states without an international-standard regulator of their own.<\/p>\n\n\n\n<p>It also opens the door for the jabs to enter the Covax global vaccine-sharing scheme, which aims to provide equitable access to doses around the world and particularly in poorer countries.<\/p>\n\n\n\n<p>The Sinopharm vaccine is already in use in 42 territories around the world, fourth behind AstraZeneca (166), Pfizer-BioNTech (94) and Moderna (46).<\/p>\n\n\n\n<p>Besides China, it is being used in Algeria, Cameroon, Egypt, Hungary, Iraq, Iran, Pakistan, Peru, the United Arab Emirates, Serbia and Seychelles, among others.<\/p>\n\n\n\n<p>A clutch of other vaccines are on the road towards WHO emergency use listing, including a second Sinopharm product being made in Wuhan \u2014 the city where coronavirus was first detected.<\/p>\n\n\n\n<p>A decision is expected within days on Sinovac, a second Chinese-made vaccine already being used in 22 countries.<\/p>\n\n\n\n<p>Russia\u2019s Sputnik V vaccine is the next furthest ahead in the process. &#8212; NNN-AGENCIES<\/p>\n","protected":false},"excerpt":{"rendered":"<p>GENEVA, May 8 (NNN-AGENCIES) &#8212; The World Health Organization has approved the Sinopharm Covid-19 vaccine for emergency use \u2014 the first Chinese jab to receive the WHO\u2019s green light. The UN health agency signed off on the two-dose vaccine, which is already being deployed in dozens of countries around the world. The WHO has already [&hellip;]<\/p>\n","protected":false},"author":11,"featured_media":121816,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[213,208,215,209,217],"tags":[],"_links":{"self":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts\/121813"}],"collection":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=121813"}],"version-history":[{"count":0,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts\/121813\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/media\/121816"}],"wp:attachment":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=121813"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=121813"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=121813"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}